Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial

Ross A Soo,Eng Huat Tan,Hidetoshi Hayashi,Takashi Seto,Chia-Chi Lin,Sai-Hong Ignatius Ou,Dong-Wan Kim,Geoffrey Liu,Antonello Abbattista,Jean-François Martini,Chew Hooi Wong,Francesca Toffalorio,Benjamin J Solomon

Lung Cancer（2022）

引用 6|浏览19

暂无评分

摘要

•Substantial activity was observed in both Asian and non-Asian pretreated patients.•AE profiles were comparable between Asian and non-Asian patients.•Lorlatinib is an option in Asian ALK-positive patients after use of other ALK TKIs.

查看译文

关键词

Lorlatinib,Asian,Non-small cell lung cancer,Tyrosine kinase inhibitor,Anaplastic lymphoma kinase

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要